News

Public · Published

Canaccord Genuity maintains Merit Medical Systems at Buy, raises price target to $121 from $94

Canaccord Genuity kept its Buy rating on Merit Medical Systems and raised its price target to $121 from $94. The new target is 28.7% higher than its previous target and implies 40.3% upside from the October 30 closing price of $86.24.

Published:

Updated:

What happened

Canaccord Genuity kept its Buy rating on Merit Medical Systems and raised its price target to $121 from $94. The new target is 28.7% higher than its previous target and implies 40.3% upside from the October 30 closing price of $86.24.

Confirmed

Global impact / market context

A higher target reflects Canaccord’s more optimistic view of the company’s potential share value, but it is an analyst estimate, not a company forecast or guaranteed return. If investors act on it, buying could support the share price; the article gives no evidence of such a reaction.

Analyst inference

The five other recent analyst notes listed set targets from $90 to $110, while Canaccord’s new $121 target is above that range. This highlights a more optimistic estimate, but differences among analyst views do not establish Merit Medical’s future results or share price.

Confirmed

What to watch

  1. Compare future analyst targets with company results and outlook; the article provides estimates but no new operating figures that would confirm the higher valuation. Analyst inference
  2. Check whether other analysts raise their targets or ratings, which could show whether Canaccord’s more optimistic view is becoming more widely shared. Analyst inference
  3. Watch Merit Medical’s subsequent share price against the stated $86.24 October 30 close and Canaccord’s $121 target; the article reports no later price movement. Analyst inference

Evidence

  • Original source link unavailable